

## FROM THE JOURNALS



## Value in Health January 2019

## THEMED SECTION: EUROQOL

**Overview, Update and Lessons Learned from the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol**

Elly Stolk; Kim Rand; Kristina Ludwig; Barend Van Hout; Juan Ramos-Goni

*The authors present the challenges faced in EQ-5D-5L valuation since 2012 and how these were resolved and describe in depth a set of new challenges that have become central in currently ongoing research on how EQ-5D-5L health states should be valued and modeled.*

**Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?**

Fan Yang; Nancy Devlin; Nan Luo

*The author explores how the use of EQ-5D-5L value set and crosswalk from EQ-5D-5L to EQ-5D-3L (and use of 3L value set) would affect cost-effectiveness analysis results for England and six other countries (Canada, the Netherlands, China, Japan, South Korea and Singapore).*

## HEALTH POLICY ANALYSIS

**Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA**

Finn Boerlum Kristensen; Don Husereau; Mirjana Huic; Michael Drummond; Marc Berger; Federico Augustovski; Ken Bond; Uwe Siebert; Andrew Booth; John Bridges; Jeremy Grimshaw; Maarten Ijzerman; Daniel Ollendorf; Alric Ruether; Jitender Sharma; Allan Wailoo; Egon Jonsson

*The authors findings suggest that although many good practices have been developed in areas of assessment and some other key aspects of defining HTA processes there are also many areas where good practices are lacking.*

## Value in Health February 2019

## BRIEF REPORT

**The Internal Validity of Discrete-Choice Experiment Data: A Testing Tool for Quantitative Assessments**

F. Reed Johnson, Jui-Chen Yang; Shelby Reed

*In this article, the authors develop a tool for testing internal validity of discrete-choice experiment data, deploy the program, and collect summary test results from a sample of active health researchers to demonstrate the practical utility of the tool in a wide range of health applications.*

## HEALTH POLICY ANALYSIS

**Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in The French Regulatory Setting? The Case of New Hepatitis C Drugs**

Valerie Clement; Veronique Raimond

*This article constitutes the first attempt to draw lessons from the recent uptake of health economic evaluation of innovative drugs in the French regulatory framework.*

## PATIENT-REPORTED OUTCOMES

**Perceptions of Response Burden Associated with Completion of Patient-Reported Outcome Assessments in Oncology**

Thomas Atkinson; Carolyn Schwartz; Leah Goldstein; Iliana Garcia; Daniel Storfer; Yuelin Li; Jie Zhang; Bernanrd Bochner; Bruce Rapkin

*The authors sought to quantify patient response burden and identify its predictive factors.*

## FOR MORE INFORMATION

Visit: <https://www.ispor.org/publications/journals/value-in-health>.